Abstract
Prospects for a new biologically based strategy of cancer treatment are being discussed. While physically and chemically based therapies, such as radio- and chemotherapy, are not directed against cancer tissue only and have a suppressive effect on the immune system, immunotherapy and gene therapy, which are discussed here, try to be more selective and to stimulate rather than suppress antitumor immune mechanisms. On the basis of personal experience with these new technologies, good future prospects are predicted for the application of cancer vaccines and immune T lymphocytes for active specific immunization (ASI) and adoptive immunotherapy (ADI) respectively. While ASI strategies aim at micrometastases being affected by activated host immune T cells, and might find a place for postoperative adjuvant treatment in high-risk cancer patients, cellular therapies such as ADI do not require an intact host immune system and could therefore also find application in advanced stages of disease. In spite of the exciting new perspectives of immuno- and gene therapy for the cancer patient, this therapy is not yet a defined discipline and requires years of further research.
Similar content being viewed by others
Abbreviations
- ASI :
-
active specific immunization
- ADI :
-
adoptive immunotherapy
- TA :
-
tumor-associated antigen
- APC :
-
antigen-presenting cells
- CAM :
-
cell-adhesion molecule
- TNF :
-
tumor necrosis factor
- TIL :
-
tumor-infiltrating lymphocytes
- IFN :
-
interferon
- IL :
-
interleukin
- GM-CSF :
-
granulocyte/macrophage-colony-stimulating factor
- NDV :
-
Newcastle disease virus
- CTL :
-
cytotoxic T lymphocytes
References
Balkwill FR (1989) Peptide regulatory factors-Interferons. Lancet 1: 1060–1063
Boon T, Coulie P, Marchand M, Weynants P, Wölfel T, Brichard V (1994) Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. In: De Vita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology 1994. Lippincott, Philadelphia, pp 53–69
Bubenik J (1993) IL-2 and gene therapy of cancer (review) Int J Oncol 2: 1049–1052
Cassel WA, Murray DR, Phillips HS (1983) A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 52: 856–860
Csatary LK, Eckhardt S, et al (1993) Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prevent 17: 619–627
Desai PB (1994) Guest editorial. Understanding the biology of cancer: has this any impact on treatment? J Cancer Res Clin Oncol 120: 193–199
Ertel C, Millar NS, Emmerson PT, Schirrmacher V, Hoegen P von (1993) Viral hemagglutinin augments peptide specific cytotoxic T cell responses. Eur J Immunol 23: 2592–2596
Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T-helper function in the generation of an antitumor response. Cell 60: 397–403
Goldman JM, Gale RP, Horowitz, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobson SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM (1988) Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for replapse associated with T-cell depletion. Ann Intern Med 108: 806–814
Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254: 713–716
Heicappell R, Schirrmacher V, Hoegen P von, Ahlert T, Appelhans B (1986) Prevention of metastastic spread by postoperative immunotherapy with virally modified autologous tumor cells. Int J Cancer 37: 569–577
Hoover HC, Brandhorst JS, Peters LC, Surdyke MG, Takeshita Y, Madariaga J, Muenz LR, Hanna MG (1993) Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 11: 390–399
Houghton AN (1994) Cancer antigens: immune recognition of self and altered self. J Exp Med 180: 1–4
Hwu P, Rosenberg SA (1994) The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials. Cancer Detect Prevent 18: 43–50
June CH, Bluestone JA, Nadler LM, Thompson CB (1994) The B7 and CD28 receptor families. Immunol Today 15: 321–331
Kaido T, Maury C, Schirrmacher V, Gresser I (1994) Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T-cells and IFN-α/β. Int J Cancer 57: 538–543
Kenney S, Pagano JS (1994) Editorial: viruses as oncolytic agents: a new age for “therapeutic” viruses? J Natl Cancer Inst 86: 1185
Khazaie K, Prifti S, Beckhove P, Griesbach A, Russel S, Collins M, Schirrmacher V (1994) Persistence of dormant tumor-cells in the bone marrow of tumor-cell-vaccinated mice correlates with long term immunological protection. Proc Natl Acad Sci USA 91: 7430–7434
Kobayashi H (1979) Viral xenogenization of intact tumor cells. Adv Cancer Res 30: 279–299
Krüger A, Umansky V, Rocha M, Hacker HJ, Schirrmacher V, Hoegen P von (1994) Pattern and load of spontaneous liver metastasis dependent on host immune status studied with alacZ transduced lymphoma. Blood 84: 3166–3174
Kumar L (1994) Leukemia: management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 12: 1710–1717
Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL (1995) Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. The Lancet 345: 1016–1020
Liebrich W, Schlag P, Manasterski M, Lehner B, Stöhr M, Möller P, Schirrmacher V (1991) In vitro and clinical characterization of a Newcastle disease virus-modified autologous tumor cell vaccine for treatment of colorectal cancer patients. Eur J Cancer 27: 703–710
Lorence RM, Reichard KW, Katubig BB, et al (1994) Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst 86: 1228–1233
Matzinger P (1994) Tolerance, danger and the extended family. Annu Rev Immunol 12: 991–1045
Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman PJ, Underleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Maillard IA (1990) Levamisole and fluoruracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 252–258
Ockert D, Schirrmacher V, Beck N, Stoelben E, Ahlert T, Flechtenmacher J, Hagmüller E, Nagel M, Saeger H-D (1995) Newcastle disease virus infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res (in press)
O'Connell MJ, Colgan JP, Oken MM, et al (1986) Clinical trial of Recombinant Leucocyte A Interferon as Initial Therapy for Favorable Histology Non-Hodgkin's Lymphomas and Chronic Lymphocytic Leukemia. An Eastern Cooperative Oncology Group Pilot Study. J Clin Oncol 42: 128–136
Plaksin D, Progador A, Vadai E, Feldman M, Schirrmacher V, Eisenbach L (1994) Effective anti metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV). Int J Cancer 59: 796–804
Pomer S, Schirrmacher V, Thiele R, Löhrke H, Staehler G (1995) Tumor response and 4 year survival data of patients with advanced renal cell carcinoma treated with autologous tumor vaccine and subcutaneous r-IL-2 and IFN-alpha 2b. Int J Oncol 6: 947–954
Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L (1993) Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, interferon-γ genes. J Immunother 14: 191–201
Restifo NP, Kawakami Y, Marincola F, Shamamian P, Taggarse A, Esquivel F, Rosenberg SA (1993) Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class. J Immunother 14: 182–190
Ritz J (1994) Tumor immunity: Will new keys unlock the door? J Clin Oncol 12: 237–238
Rosenberg SA, Lotze MT, Yang IC, et al (1993) Prospective randomized trial of high dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85: 622–632
Schild HJ, Hoegen P von, Schirrmacher V (1988) Modification of tumor cells by low dose of Newcastle disease virus. II. Augmented tumor specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation. Cancer Immunol Immunother 28: 22–28
Schirrmacher V (1990) Krebsimpfung mit Tumorzellen. Spectrum der Wissenschaft, Januarheft: 38–50
Schirrmacher V (1992) Immunity and metastasis: in situ activation of protective T cells by virus-modified cancer vaccines. Cancer Surv 13: 129–154
Schirrmacher V (1993) Active specific immunotherapy (ASI)—a new modality of cancer treatment involving the patients own immune system. Onkologie 16: 290–296
Schirrmacher V, Hoegen P von (1993) Importance of tumor cell membrane integrity and viability for CTL activation by cancer vaccines. Vaccine Res 2: 183–196
Schirrmacher V, Schild H-J, Gückel B, Hoegen P von (1992) Tumor specific CTL response requiring interactions of four different cell types and dual recognition of MHC class I and II restricted tumor antigens. Immunol Cell Biol 71: 311–326
Schirrmacher V, Griesbach A, Zangemeister-Wittke U (1994) γ-irradiated viable tumor cells as whole cell vaccines can stimulate in situ syngeneic anti-tumor CTL and DTH reactivity while tumor cell lysates elicit only DTH reactivity. Vaccine Res 3: 31–48
Schirrmacher V, Beckhove P, Krüger A, Rocha M, Umansky V, Fichtner K-P, Hull WE, Zangemeister-Wittke U, Griesbach A, Jurianz K, Hoegen P von (1995) Effective immune rejection of advanced metastasized cancer. Intern J Oncol 6: 505–521
Schlag P, Manasterski M, Gerneth Th, Hohenberger P, Dueck M, Herfarth Ch, Liebrich W, Schirrmacher V (1992) Active specific immunotherapy with NDV modified autologous tumor cells following liver metastases resection in colorectal cancer: first evaluation of clinical response of a phase II trial. Cancer Immunol Immunother 35: 325–330
Schwartz RH (1990) A cell culture model for T lymphocyte clonal anergy. Science 248: 1349–1356
Slavin S, Ackerstein A, Weiss L, Nagler A, Reuven O, Naparstek E (1992) Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest 10: 221–227
Hoegen P von, Zawatzky R, Schirrmacher V (1990) Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor specific cytolytic T cell activity via induction of interferon, alfa, beta. Cell Immunol 126: 80–90
Author information
Authors and Affiliations
Additional information
In honour of Prof. G. Schwenker, Heidelberg, on the occasion of his 70. birthday
TheJournal of Cancer Research and Clinical Oncology occasionally publishes Editorials and Guest Editorials on current and controversial problems in experimental and clinical oncology. These papers reflect the personal opinions of the authors. Readers should send any comments directly to the authors
Rights and permissions
About this article
Cite this article
Schirrmacher, V., Hagmüller, E., Lehnert, T. et al. Biotherapy of cancer. J Cancer Res Clin Oncol 121, 443–451 (1995). https://doi.org/10.1007/BF01218359
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01218359